Skip to content
Emerging Research

KPV

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH).

Also known as: Anti-Inflammatory Tripeptide, Alpha-MSH Fragment

Typical Dose 200-300mcg
Storage Refrigerate reconstituted; store lyophilized powder away from light
How Often Once daily

Overview

KPV is a potent anti-inflammatory tripeptide derived from the C-terminal fragment of alpha-melanocyte-stimulating hormone (α-MSH). This small but powerful peptide exhibits remarkable anti-inflammatory and antimicrobial properties without the pigmentation effects of full α-MSH. KPV has shown particular promise for inflammatory bowel diseases, skin conditions, and immune modulation through its ability to penetrate cells and interact directly with inflammatory signaling pathways.

Key Benefits

  • Systemic Inflammation
  • Autoimmune Modulation
  • Joint Inflammation

Systemic anti-inflammatory effects, immune modulation, potential for autoimmune conditions

Mechanism of Action

Enters cells and inhibits inflammatory pathways at the nuclear level, particularly NF-κB signaling

Pharmacokinetics

Peak plasma concentration: 3 min. Elimination half-life: 30 min. Largely cleared by: ~2.5 hrs.

Research Protocols Injectable

GoalDoseFrequencyRoute
General Anti-Inflammatory200-300mcgOnce dailySubcutaneous
Active Inflammation250mcgTwice dailySubcutaneous
Autoimmune Support500mcgOnce dailySubcutaneous
Acute Flare-ups500mcgTwice daily for 1 week then reduceSubcutaneous

Research protocols from published literature — not dosing recommendations.

Peptide Interactions

  • BPC-157 — Synergistic: Complementary gut healing mechanisms - BPC-157 promotes tissue repair while KPV reduces inflammation
  • TB-500 — Compatible: Both have anti-inflammatory properties through different pathways - may work well together
  • LL-37 — Synergistic: Both are antimicrobial peptides - KPV focuses on inflammation while LL-37 on direct antimicrobial action
  • Thymosin Alpha-1 — Compatible: Different immune modulation mechanisms - TA1 enhances immune function while KPV reduces inflammation
  • GHK-Cu — Synergistic for Skin: Excellent combination for skin health - GHK-Cu promotes collagen while KPV reduces inflammation
  • Melanotan II — Use Caution: KPV is derived from α-MSH like MT-II but without tanning effects - using both is unnecessary

Peptide Instructions Injectable

Supplies:

  • KPV peptide vial
  • Bacteriostatic water
  • Insulin syringes
  • Alcohol prep pads

How to Reconstitute Injectable

  1. 1Clean vial top with alcohol pad
  2. 2Add 1mL bacteriostatic water to 1mg vial (creates 1000mcg/mL)
  3. 3For easier dosing: Add 2mL to 1mg vial (creates 500mcg/mL)
  4. 4Gently swirl to mix - KPV dissolves easily
  5. 5Solution should be clear and colorless
  6. 6Label with concentration and date

What to Expect Injectable

Day 1-3: Subtle reduction in inflammation, improved energy. Week 1: Noticeable decrease in inflammatory symptoms. Week 2-3: Improved gut function, reduced pain/swelling. Week 4: Significant improvement in target condition. Week 6-8: Sustained anti-inflammatory benefits, improved quality of life.

Side Effects & Safety

Excellent safety profile with minimal side effects. Does not cause immunosuppression like steroids. No melanin production or tanning effects. May temporarily reduce inflammation-related symptoms. Monitor for signs of infection (rare). Generally well-tolerated even at higher doses.

Excellent safety profile with minimal side effects. Does not cause immunosuppression like steroids. No melanin production or tanning effects. May temporarily reduce inflammation-related symptoms. Monitor for signs of infection (rare). Generally well-tolerated even at higher doses.

Community Insights

KPV should be stored at Refrigerate after reconstitution, stable for 30-45 days.

References

  1. Antimicrobial Properties Against Gut Pathogens (2022) · 2022
  2. KPV for Psoriasis and Dermatitis (2021) · 2021
  3. Anti-Inflammatory Mechanisms of KPV (2020) · 2020
  4. KPV in Inflammatory Bowel Disease Models (2019) · 2019

Research reference only. Not medical advice.